Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02736383
NCT02736383CompletedNot Applicable

Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery

Spectrum Health Hospitals0 sites142 target enrollmentStarted: May 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
142
Primary Endpoint
Blood Transfusion Rate
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging.
  • •Age 65 and older
  • •Low energy mechanism of injury
  • •Hip fracture fixation performed within 48 hours
  • •English speaking
  • •Anticipated medical optimization for operative fixation
  • •No other major trauma

Exclusion Criteria

  • •Retained hardware around the affected hip
  • •Infection around the affected hip
  • •Transfer patients with a length of stay > 24 hours at the transferring hospital
  • •Diagnosis of deficient natural anticoagulation
  • •Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)
  • •Known allergy to TXA
  • •Patients undergoing percutaneous pinning of the hip fracture

Outcomes

Primary Outcomes

Blood Transfusion Rate

Time Frame: 6 weeks

Blood transfusion rates during the patients hospital stay will be assessed.

Secondary Outcomes

  • Hospital Length of stay(6 weeks)
  • Post operative complications(6 weeks)
  • Hospitalization costs(6 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Completed
Phase 4
Tranexamic Acid in Trauma Surgery Tranexamic Acid in Trauma Surgery Tranexamic Acid in Trauma SurgeryTranexamic AcidTraumaLower Extremity Fracture
NCT04986813Jaspreet Singh100
Withdrawn
Phase 4
The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip FracturesBlood LossHip Fracture
NCT01940536Hospital for Special Surgery, New York
Unknown
Phase 3
Use of Transexamic Acid in Hip ReplacementBleedingTransfusion Related Complication
NCT02587845Samsung Medical Center150
Unknown
Phase 2
Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal SurgeryHepatocellular CancerPancreatic CancerGastric CancerColon Cancer
NCT01655641Tribhuvan University Teaching Hospital, Institute Of Medicine.118
Completed
Not Applicable
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas ResectionSeizuresMeningioma
NCT04595786Beijing Tiantan Hospital228